Statistical innovation is vital in the pharmaceutical industry as it drives evidence-based decisions and brings value to patients. However, it requires a delicate balance between invention and commercialization to achieve success.

I, together with Mouna Akacha and Kaspar Rufibach - two leaders of statistical innovation groups in big pharma companies, share their insights on the barriers and strategic planning in driving statistical innovation. In this first part of the episode, we will discuss their perspectives on commercializing statistical inventions, leveraging external resources, collaboration, and setting up a community of statistical methodology leaders.

Join us while we also discuss the following points: